The Health Policy Forum has been tracking implementation of the Affordable Care Act through published research, media and government resources. In the coming months, we hope to launch a detailed study of insurance coverage in Texas. Additionally, with funding from the National Cancer Institute, we are completing manuscripts for a study of the cost drivers of complex cancer surgery. Other projects include an analysis of regional variations of cancer treatment in Texas, a study of the effect of smoking bans on hospitalization rates, and a study of whether shared savings programs for physicians can reduce overall patient health care expenditures.
John Mendelsohn, M.D., is a Nonresident Fellow in Biomedical Research Policy at the Baker Institute. His work focuses on the identification and evaluation of new health technologies, therapeutics and best practices, as well as the promotion of policy recommendations to improve national and global health outcomes.
Until September 2011, Mendelsohn served as president of The University of Texas MD Anderson Cancer Center in Houston. Prior to joining the Baker Institute, he was on sabbatical at the Broad Institute of MIT and Harvard. He remains on the MD Anderson faculty as director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.
Before joining MD Anderson, Mendelsohn led the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He also held the Winthrop Rockefeller Chair in Medical Oncology and served as co-head of the Program in Molecular Pharmacology and Therapeutics. Additionally, he was professor and vice chairman of medicine at Cornell University Medical College. Previously, Mendelsohn was founding director of a National Cancer Institute-designated cancer center at the University of California, San Diego. His research helped pioneer the development of cancer therapies that target the aberrant genes, gene products and cell-signaling pathways that cause the disease.
Mendelsohn has received the Fulbright Lifetime Achievement Medal (2005); the Dan David Prize in Cancer Therapy (2006); and the Lila Gruber Memorial Cancer Research Award and the Lifetime Achievement Award from the 10th International Workshop on Molecular Targeted Therapy of Cancer (2009).
He holds a bachelor’s degree in biochemical sciences magna cum laude from Harvard College and a medical degree cum laude from Harvard Medical School.